Analysts Expect Zoetis Inc (ZTS) Will Post Quarterly Sales of $1.41 Billion
Wall Street brokerages forecast that Zoetis Inc (NYSE:ZTS) will report sales of $1.41 billion for the current quarter, according to Zacks. Five analysts have provided estimates for Zoetis’ earnings, with estimates ranging from $1.39 billion to $1.42 billion. Zoetis reported sales of $1.28 billion during the same quarter last year, which indicates a positive year-over-year growth rate of 10.2%. The firm is expected to report its next quarterly earnings results on Thursday, February 15th.
According to Zacks, analysts expect that Zoetis will report full-year sales of $1.41 billion for the current year, with estimates ranging from $5.24 billion to $5.27 billion. For the next financial year, analysts anticipate that the company will post sales of $5.63 billion per share, with estimates ranging from $5.57 billion to $5.69 billion. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Zoetis.
Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, November 2nd. The company reported $0.65 earnings per share for the quarter, beating the consensus estimate of $0.63 by $0.02. Zoetis had a return on equity of 62.39% and a net margin of 18.29%. The company had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.32 billion. During the same period in the prior year, the business earned $0.52 earnings per share. Zoetis’s revenue for the quarter was up 8.5% compared to the same quarter last year.
Institutional investors have recently added to or reduced their stakes in the business. Northwestern Mutual Wealth Management Co. raised its stake in Zoetis by 16.8% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock worth $100,000 after acquiring an additional 230 shares in the last quarter. Steward Partners Investment Advisory LLC acquired a new position in Zoetis during the third quarter worth $114,000. Harfst & Associates Inc. raised its stake in Zoetis by 16.1% during the second quarter. Harfst & Associates Inc. now owns 1,878 shares of the company’s stock worth $117,000 after acquiring an additional 260 shares in the last quarter. Almanack Investment Partners LLC. acquired a new position in Zoetis during the second quarter worth $119,000. Finally, Mitsubishi UFJ Securities Holdings Co. Ltd. raised its stake in Zoetis by 251.9% during the third quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,900 shares of the company’s stock worth $121,000 after acquiring an additional 1,360 shares in the last quarter. Hedge funds and other institutional investors own 93.33% of the company’s stock.
Shares of Zoetis (ZTS) opened at $72.38 on Thursday. Zoetis has a 12-month low of $50.57 and a 12-month high of $72.99. The company has a debt-to-equity ratio of 2.45, a current ratio of 2.80 and a quick ratio of 1.95. The firm has a market capitalization of $35,196.84, a P/E ratio of 33.13, a PEG ratio of 2.17 and a beta of 1.06.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, January 19th will be paid a dividend of $0.126 per share. This is a positive change from Zoetis’s previous quarterly dividend of $0.11. This represents a $0.50 annualized dividend and a yield of 0.70%. The ex-dividend date of this dividend is Thursday, January 18th. Zoetis’s dividend payout ratio is currently 22.11%.
COPYRIGHT VIOLATION NOTICE: “Analysts Expect Zoetis Inc (ZTS) Will Post Quarterly Sales of $1.41 Billion” was published by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/12/14/analysts-expect-zoetis-inc-zts-will-post-quarterly-sales-of-1-41-billion.html.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.